Multidrug-resistant
INTRODUCTION
Acinetobacter baumannii, among the most important causes of nosocomial infections, is becoming a serious threat for hospitalized patients because of increasing antibiotic resistance rates. In recently conducted surveillance studies, it has been reported that resistance is increasing among carbapenems, which are still considered as the primary treatment against these bacteria. Thus, they have become among the most difficult nosocomial Gram-negative pathogens to control and treat (Jain and Danziger, 2004; Lockhart et al., 2007 have necessitated administration of combination therapies as an alternative choice for the treatment of multidrug-resistant A. baumannii (MDR-AB) infections and consequently empirical combination therapies have become common in practice (Bonapace et al., 2000) . It is anticipated that the addition of other active antimicrobials to carbapenem may save its role as a core antimicrobial to fight against infections due to MDR-AB (Pongpech et al., 2010) . Previous research evaluating the activity of rifampin against A. baumannii isolates indicated that rifampin shows in vitro bactericidal activity against these bacteria (Thornsberry et al., 1983) . Furthermore, synergism was observed with the combination of rifampin plus imipenem (Tripodi et al., 2007) . Sulbactam is another interesting antimicrobial agent that possesses the highest intrinsic antibacterial activity among β lactamase inhibitors against A. baumannii with minimal side effects (Peleg et al., 2008) . The combination of ampicillin-sulbactam or sulbactam alone with carbapenems has been reported to improve the activity of β-lactams against MDR-AB isolates significantly (Ko et al., 2004; Wang et al., 2004) . With limited therapeutic options in MDR-AB infections, clinicians have returned to the use of old class of antibiotics like polymyxin B and colistin which were abandoned during previous years in most parts of the world because of their unfavorable effects. Since most of the MDR-AB isolates are found to be susceptible to polymyxins they have been accepted as savior agents and despite security concerns about toxicity, clinicians tend to use polymyxins for the treatment of infections caused by MDR-AB (Peleg et al., 2008) .
Antimicrobial susceptibility testing of A. baumannii has shown equally high susceptibility rates for polymyxin B (95 to 99%) and for colistin (98 to 100%) (Diez et al., 2004; Landman et al., 2007; Manikal et al., 2000) . However, the emergence of resistance during treatment when used alone and potentially toxic effects have given rise to the use of polymyxins in combinations instead of increasing the dose as a single agent. Frequently preferred antimicrobials for this purpose are carbapenems like imipenem, meropenem or doripenem. While there are various reports about polymyxin that synergistic activity is obtained with this drug when used in combination therapies, it is also known that the results of synergy tests with polymyxin are highly strain and method dependent and in vitro synergy may or may not translate into in vivo benefit (Pankey and Ashcraft, 2009; Wareham and Bean, 2006) . In this study, the antibacterial effect of imipenem and meropenem in combination with cefoperazone-sulbactam, ampicillin-sulbactam, polymyxin B and rifampin was evaluated in vitro by the checkerboard microdilution method against 34 clinical isolates of MDR-AB.
MATERIALS AND METHODS

Bacterial isolates
The MDR-AB phenotype was defined as A. baumannii isolates resistant to at least three different antimicrobial classes of traditional antimicrobials. Thirty-four A.baumannii strains which were determined to be resistant to ticarcillin, cefepime, amikacin and ciprofloxacin besides imipenem and meropenem by disc diffusion method according to Clinical and Laboratory Standards Institute (CLSI) recommendations have been included in this study (Clinical and Laboratory Standards Institute, 2010 
Antimicrobial agents and minimum inhibitory concentration (MIC) assays
The antimicrobial agents used in combinations were: imipenem, meropenem, cefoperazone-sulbactam, ampicillin-sulbactam, polymyxin B and rifampin. All agents were purchased from individual pharmaceutical companies as standard reference powders for laboratory use and they were obtained from SigmaAldrich (Taufkirchen, Germany), except sulbactam (Zhejiang Xinhua Pharmaceutical Co. Ltd). Antimicrobial stock solutions were prepared by solvents and diluents according to CLSI standards and stored at -80°C (Clinical and Laboratory Standards Institute, 2010) . MIC values of all isolates for each antibiotic were determined by broth microdilution method, using standard inoculum with 0.5 McFarland diluted with cation-adjusted Mueller Hinton II broth (BD, BBL) in a ratio of 1:100 and a final concentration of 5x10 5 CFU/mL. Following this step, microtiter plates were visually read after incubation for 24 h at 37°C. The concentration range tested was 0.0625 to 128 mg/L for imipenem, 0.0625 to 128 mg/L for meropenem, 0.125 to 256 mg/L for ampicillin-sulbactam, 0.25 to 512 mg/L for cefoperazone-sulbactam, 0.031 to 64 mg/L for rifampin and 0.001 to 4 mg/L for polymyxin B. Procedures followed the descriptions of CLSI protocols (Clinical and Laboratory Standards Institute, 2010) . Escherichia coli ATCC 25922 was used as internal quality control strain in each susceptibility test.
MIC results were interpreted according to the CLSI breakpoint criteria for A. baumannii. Since there are no CLSI interpretation criteria relevant to A. baumannii for cefoperazone-sulbactam and rifampin, the susceptibility breakpoints for these antibiotics were based on the MIC interpretive standards of CLSI for other nonenterobacteriaceae and Gram-positive bacteria, respectively (Clinical and Laboratory Standards Institute, 2010).
Checkerboard assay
The activity of the antimicrobial combinations were determined using the checkerboard assay (Pillai et al., 2005) . The range of concentrations was determined according to the previously assessed MIC of each antibiotic for each isolate. Concentrations tested ranged from 0.03xMIC to 4xMIC of each antibiotic. The twofold dilutions of antibiotics were prepared in sterilized tubes and 25 µL of each antimicrobial agent in each combination was added in 96-well checkerboard plates making up a total of 50 µL in each well. Then 50 µL of 1/100 diluted 0.5 McFarland bacterial suspension of A. baumannii was added to each well forming a final concentration of the test strains as approximately 5 × 10 5 CFU/mL. The plates then were incubated at 37°C for 20 h. Positive and negative controls were performed once for each combination. The positive control wells contained a mixture of broth and bacterial suspension and the negative control wells contained broth without bacteria. MICs and fractional inhibitory concentrations (FICs) were determined after overnight incubation by examining for turbidity. The absence of viable cells in non-turbid wells was confirmed by the addition of alamar blue reagent (Sigma-Aldrich, Germany), which turns the wells containing active bacteria to red. The interpretation of the checkerboard synergy testing results was determined with the method of Anon in which the lowest FIC index (FICI) of all the non-turbid wells along the turbidity/non-turbidity interface was used (Anon, 1992) . FICIs and FICI were calculated for each antimicrobial combination using the formulas below: FICI results for each combination were defined as synergy for FICI≤0.5, additivity for 0.5 < FICI ≤ 1, indifference for 1< FICI < 4 and antagonism for FICI ≥ 4 (Pillai et al., 2005) . Table 3 .
RESULTS
Specimen
DISCUSSION
In this study, the highest synergy rates were observed for the combinations of meropenem plus ampicillinsulbactam (94.1%) and imipenem plus ampicillinsulbactam (88.2%). In accordance with our findings, high synergy rates have been reported in many previous Özseven et al. 2987 studies investigating in vitro synergistic activities of carbapenems with sulbactam containing agents (Kiratisin et al., 2010; Ko et al., 2004; Pongpech et al., 2010) . Moreover, among one of the few clinical studies, Lee et al. (2007) reported favorable clinical outcomes with carbapenem-sulbactam combination therapy in 4 critically ill patients with bacteremia who were infected by MDR-AB isolates showing resistance to both agents. The high rates of synergism found for carbapenems in combination with agents containing sulbactam have led us to think that these combinations may be good alternatives for the treatment of MDR-AB infections. However, while synergy was detected among 70.6% of the strains for imipenem plus cefoperazone-sulbactam, the synergistic effect of meropenem combined with cefoperazone-sulbactam was significantly lower than the other sulbactam combinations (8.8%). The reason of this discordant finding may be attributed to the fact that synergy was defined as an FICI of ≤ 0.5 in our study. As a matter of fact, 64.7% of the strains showed FICI of ≤ 1 for meropenem plus cefoperazone-sulbactam combination.
Moreover, although synergy rates were generally lower for combinations with meropenem than imipenem, important proportion of the strains showed FICI of ≤ 1 for combinations with meropenem. Various reports defining synergism as FICI ≤ 1 would support our approach to this subject (Pongpech et al., 2010; Yoon et al., 2004) .
In the present study, we have also searched the activity of carbapenems in combination with rifampin and we determined in vitro synergistic interactions between imipenem and rifampin against 73.5% of the isolates while meropenem+rifampin combination showed synergistic activity among only 17.6% of the tested strains. Antagonistic activity was detected among none of the strains for these two combinations. Several researchers investigating the activity of combination regimens against MDR-AB infections have also tested nontraditional agents like rifampin. Rifampin has been considered as inactive against Gram-negative bacteria due to its hydrophobicity, negative charge and large molecular size, all of which could decrease its outer membrane permeability (Song et al., 2009 ). However, in several in vitro studies it has been reported that the combinations of rifampin with carbapenems, ampicillinsulbactam and polymyxins which are used against Gramnegative bacteria act synergistically against multidrug and especially carbapenem-resistant A. baumannii (Giamarellos-Bourboulis et al., 2001; Hogg et al., 1998; Tascini et al., 1998) . Tripodi et al. (2007) reported in their study with time-kill method that regrowth was seen in isolates at 24 h when imipenem and rifampin were used alone but a significant synergism was determined between these antibiotics against all imipenem-resistant isolates. Moreover they also reported that the rapidly developing resistance in rifampin when used alone was blunted by the addition of imipenem suggesting that the combination therapies may be more effective than monotherapy. The observation of high synergistic activity for imipenem+rifampin combination in our study was in accordance with these reports. This high synergistic activity had possibly been related to substantial changes that might have occurred in the outer membrane of carbapenem-resistant A. baumannii isolates, thus they would permit rifampin to penetrate into the cell (Li et al., 2007) . In our study, when we consider the high percentages of synergistic and partial synergistic effects evaluated with carbapenems and rifampin (for imipenem plus rifampin: 100% and for meropenem plus rifampin: 94.1%) we can predict that these combinations would individually be alternative therapeutic options for the treatment of MDR-AB infections. On the other hand, although it has been reported in a clinical study that 7 of 10 patients suffering from serious infections due to carbapenem-resistant A. baumannii isolates were cured with imipenem+rifampin combination therapy (70%), high-level rifampin-resistance developed in seven strains (70%) suggesting the limitation of this agent in clinical use (Saballs et al., 2006) .
Several in vitro studies have tested a carbapenem with a polymyxin in combination against carbapenem-resistant A. baumannii isolates (Pankey and Ashcraft, 2009; Pongpech et al., 2010; Tripodi et al., 2007; Wareham and Bean, 2006; Yoon et al., 2004) . In our study, synergistic activity was observed among 38.2% of tested strains for imipenem+polymyxin B combination, while this rate was 2.9% for meropenem+polymyxin B combination. Higher additive interaction rates were found for both combinations (55.9 and 64.7%, respectively). Although a four-fold reduction was detected in the MIC value of carbapenem in the combination among most of the isolates, the synergy rates were lower than the rates that we observed within the other carbapenem based combinations. The possible reason is that the isolates we used in this study were susceptible to polymyxin B with lowlevel MIC values (MIC ≤ 0.125 µg/ml). In fact, the synergy rate evaluated for imipenem+polymyxin B combination was at a level that should not be underestimated (38.2%) and is in accordance with the study of Wareham and Bean (2006) in which they reported 40% synergistic activity between imipenem and polymyxin B against imipenem-resistant and polymyxin B-susceptible A. baumannii isolates. Pongpech et al. (2010) , in their study with 30 MDR-AB isolates all resistant to imipenem and meropenem, have observed 100% synergistic activity between imipenem and colistin by the checkerboard and time-kill methods and have demonstrated major morpho-logical damages with scanning electron microscopy indicating that the synergistic effect may be related to weakening of cell wall or membrane due to actions of colistin. There are several other studies reporting higher levels of synergy relevant to this combination. In a recent study, Pankey and Ashcraft (Pankey and Ashcraft, 2009) demonstrated in vitro synergy between meropenem and polymyxin B against genetically unique 8 meropenem-resistant A. baumannii strains by time-kill assay (100%) and Etest (63%). In the time-kill study by Tripodi et al. (2007) it has been reported thatcolistin showed bactericidal activity when used both alone or in combination with imipenem however it has also been reported that combination of colistin with imipenem would not provide any additional advantage. In this regard, it has been suggested that if the bacterial isolates are susceptible to one of the agents in the combination it will be preferable to use monotherapy instead of combi-nation. However, owing to its poor diffusion into lung epithelial lining fluid, the use of polymyxin as a single agent may be inadequate especially in A. baumannii pneumonia (GarnachoMontero et al., 2003) . Moreover, Landman et al. (2005) reported that the increased use of polymyxin B as a single agent for the treatment of A. baumannii infections susceptible only to polymyxins have caused an increase in the incidence of Pseudomonas aeruginosa isolates resistant to polymyxins. In a recently conducted study, Falagas et al. (2010) reported that patients who were treated with colistin meropenem combination had a better outcome of infection than patients who received colistin in combination with other antimicrobials. The authors further noted that although there was no statistically significant difference in clinical outcome found between monotherapy of colistin and colistin+meropenem combination therapy, the use of combination is preferable since heteroresistance may arise when colistin is used alone (Falagas et al., 2010) . Since antagonism was not detected for both combinations in our study, it can be suggested that the use of these combinations against A. baumannii might be an alternative choice. Furthermore, adding a carbapenem to the treatment at maximum concentration without increasing the dosage of polymyxin, will probably enhance the bactericidal effect and reduce the toxicity of polymyxin.
In conclusion, owing to the high percentages of synergistic interactions between a carbapenem (especially imipenem) and ampicillin-sulbactam, cefoperazone-sulbactam, rifampin or polymyxin B and because no antagonism was detected in our study, these combinations are of considerable interest and may Özseven et al. 2991 provide a rationale for innovative and effective therapeutic options for infections caused by MDR-AB. If combination therapy is preferred, the combinations which are known to be effective might be used empirically in the light of previous in vitro studies. However, since synergistic activity may depend on bacterial strains and susceptibility testing methods, it must be emphasized that evaluating the efficacy of combinations against isolates by synergy tests is essential to guide the treatment properly. Further comprehensive studies with clinical evidence are also warranted.
